Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Labs

This article was originally published in The Tan Sheet

Executive Summary

Ross Products' "more normalized mid-single digit sales growth" for pediatric nutritionals business expected by mid-year or in second half of 2002 following division's 2.6% growth in 2001, Abbott Labs Division VP-Investor Relations John Thomas tells analysts Jan. 16. Ross revenue for year reached $2.08 bil.; Q4 sales were down 1.6% to $485 mil., with Thomas citing negative impact of "heavy competitive spending." Abbott is eyeing increased promotional activity, Q1 launch of Similac with Iron containing DHA/ARA fatty acids to boost pediatric nutritional sales (1"The Tan Sheet" Jan. 14, 2002, p. 3). Consolidated sales for Q4 and year were $4.45 bil (up 20%) and $16.29 bil. (up 18.5%), respectively. Earnings, including one-time charges, were $613.5 mil. for quarter, down 18.6%, and $1.55 bil. for year, a 44.4% drop...

You may also be interested in...

Mead DHA/ARA-Fortified Infant Formula Slated For February Release

Mead Johnson Nutritionals' Enfamil LIPIL, an infant formula fortified with ARA and DHA fatty acid oils, will be priced in the U.S. at a 10%-15% premium to the line's Enfamil with Iron product, the firm said

BrainCool Seeks De Novo For Device That Prevents Oral Mucositis In Cancer Patients

Results of a pivotal trial show BrainCool’s Cooral system is significantly more effective than the standard of care therapy in preventing oral mucositis in lymphoma patients.

Indo-German Collaboration Delivers Novel Diabetic Foot Ulcer Treatment

Centaur-CytoTools introduces novel topical treatment for diabetic foot ulcers in India, for which they see limited direct competition and hope to change the way the difficult-to-treat diabetes complication is managed. Phase III studies are ongoing in Europe.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts